Stockholders' Equity Attributable to Parent in USD of Nabriva Therapeutics plc from Q4 2013 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
Nabriva Therapeutics plc quarterly Stockholders' Equity Attributable to Parent history and change rate from Q4 2013 to Q2 2023.
  • Nabriva Therapeutics plc Stockholders' Equity Attributable to Parent for the quarter ending 30 Jun 2023 was $16,321,000, a 147% decline year-over-year.
Source SEC data
View on sec.gov
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)

Nabriva Therapeutics plc Quarterly Stockholders' Equity Attributable to Parent (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $16,321,000 -$50,926,000 -147% 30 Jun 2023 10-Q 19 Oct 2023 2023 Q2
Q1 2023 $4,357,000 -$48,982,000 -110% 31 Mar 2023 10-Q 19 Oct 2023 2023 Q2
Q4 2022 $3,293,000 -$50,057,000 -94% 31 Dec 2022 10-Q 19 Oct 2023 2023 Q2
Q3 2022 $25,623,000 -$37,667,000 -60% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $34,605,000 -$34,596,000 -50% 30 Jun 2022 10-Q 19 Oct 2023 2023 Q2
Q1 2022 $44,625,000 -$10,366,000 -19% 31 Mar 2022 10-Q 19 Oct 2023 2023 Q2
Q4 2021 $53,350,000 +$20,215,000 +61% 31 Dec 2021 10-Q 19 Oct 2023 2023 Q2
Q3 2021 $63,290,000 +$27,061,000 +75% 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $69,201,000 +$24,740,000 +56% 30 Jun 2021 10-Q 10 Nov 2022 2022 Q3
Q1 2021 $54,991,000 +$35,077,000 +176% 31 Mar 2021 10-Q 10 Nov 2022 2022 Q3
Q4 2020 $33,135,000 -$8,139,000 -20% 31 Dec 2020 10-K 17 Apr 2023 2022 FY
Q3 2020 $36,229,000 -$2,986,000 -7.6% 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $44,461,000 +$1,056,000 +2.4% 30 Jun 2020 10-Q 09 Nov 2021 2021 Q3
Q1 2020 $19,914,000 -$40,193,000 -67% 31 Mar 2020 10-Q 09 Nov 2021 2021 Q3
Q4 2019 $41,274,000 -$27,356,000 -40% 31 Dec 2019 10-K 17 Apr 2023 2022 FY
Q3 2019 $39,215,000 -$57,211,000 -59% 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $43,405,000 -$31,261,000 -42% 30 Jun 2019 10-Q 05 Nov 2020 2020 Q3
Q1 2019 $60,107,000 -$28,335,000 -32% 31 Mar 2019 10-Q 05 Nov 2020 2020 Q3
Q4 2018 $68,630,000 -$13,438,000 -16% 31 Dec 2018 10-K 29 Mar 2022 2021 FY
Q3 2018 $96,426,000 -$6,712,000 -6.5% 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $74,666,000 +$25,121,000 +51% 30 Jun 2018 10-Q 12 Nov 2019 2019 Q3
Q1 2018 $88,442,000 +$25,721,000 +41% 31 Mar 2018 10-Q 12 Nov 2019 2019 Q3
Q4 2017 $82,068,000 +$4,812,000 +6.2% 31 Dec 2017 10-K 11 Mar 2021 2020 FY
Q3 2017 $103,138,000 30 Sep 2017 10-Q 09 Nov 2017 2017 Q3
Q2 2017 $49,545,000 30 Jun 2017 10-Q 07 Aug 2017 2017 Q2
Q1 2017 $62,721,000 31 Mar 2017 10-Q 10 May 2017 2017 Q1
Q4 2016 $77,256,000 -$31,450,000 -29% 31 Dec 2016 10-K 12 Mar 2020 2019 FY
Q4 2015 $108,706,000 +$137,720,000 31 Dec 2015 10-K 12 Mar 2019 2018 FY
Q4 2014 $29,014,000 -$10,388,000 -56% 31 Dec 2014 10-K 16 Mar 2018 2017 FY
Q4 2013 $18,626,000 31 Dec 2013 10-K 24 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.